12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brilinta regulatory update

The European Society of Cardiology (ESC) updated its guidelines for managing acute myocardial infarction (MI) in patients presenting with persistent ST-segment elevation MI (STEMI) to include a Class I recommendation for use of AstraZeneca's marketed anti-platelet drug ticagrelor in combination with aspirin in patients undergoing primary percutaneous coronary intervention (PCI). The guidelines recommend the...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >